ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,360.79
      0.26%
      US Tech 100
      18,577.60
      0.32%
      Dow Jones
      38,868.04
      0.18%
      Brent Oil
      81.96
      3.30%
      Bitcoin
      69,634.59
      -0.03%
      Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
      Get Started
      Unknown symbol
      		Date:
      Sort by:
      DateTimeSourceHeadlineSymbolCompany
      06/10/20244:56PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:ITGartner Inc
      06/10/20244:56PMEdgar (US Regulatory)Form 424B2 - Prospectus [Rule 424(b)(2)]AMEX:XXXXMax S&P 500 4x Leveraged ETN due October 30 2043
      06/10/20244:56PMEdgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:PRAXPraxis Precision Medicines Inc
      06/10/20244:56PMBusiness WireTigo Energy soutient les installateurs résidentiels avec un programme de fidélisation présenté à l'Intersolar Europe 2024NASDAQ:TYGOTigo Energy Inc
      06/10/20244:55PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NVDANVIDIA Corporation
      06/10/20244:55PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:DBXDropbox Inc
      06/10/20244:55PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CVGWCalavo Growers Inc
      06/10/20244:55PMEdgar (US Regulatory)Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectusesAMEX:AMJBAlerian Mlp Index ETNs due January 28 2044
      06/10/20244:55PMEdgar (US Regulatory)Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectusesAMEX:AMJBAlerian Mlp Index ETNs due January 28 2044
      06/10/20244:55PMEdgar (US Regulatory)Form 424B2 - Prospectus [Rule 424(b)(2)]AMEX:AMJBAlerian Mlp Index ETNs due January 28 2044
      06/10/20244:55PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BHFAPBrighthouse Financial Inc
      06/10/20244:55PMEdgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:APDNApplied DNA Sciences Inc
      06/10/20244:55PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ATATAtour Lifestyle Holdings Ltd
      06/10/20244:55PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:AMKRAmkor Technology Inc
      06/10/20244:55PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:MMYTMakeMyTrip Limited
      06/10/20244:55PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FUSBFirst US Bancshares Inc
      06/10/20244:55PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:ITGartner Inc
      06/10/20244:55PMPR Newswire (Canada)Occupation sans droit de locaux par Québecor Média inc. : l'Assemblée nationale du Québec dépose une demande introductive d'instance pour faire respecter ses droits
      06/10/20244:54PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ABOSAcumen Pharmaceuticals Inc
      06/10/20244:54PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:BITFBitfarms Ltd
      06/10/20244:54PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:NICNicolet Bankshares Inc
      06/10/20244:54PMGlobeNewswire Inc.Le médicament Iqirvo® d’Ipsen obtient l’approbation de la FDA via une procédure accélérée comme traitement PPAR premier de sa classe thérapeutique pour la cholangite biliaire primitiveTG:I7GIpsen SA
      06/10/20244:54PMGlobeNewswire Inc.Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitisEU:IPNIpsen SA
      06/10/20244:54PMGlobeNewswire Inc.Le médicament Iqirvo® d’Ipsen obtient l’approbation de la FDA via une procédure accélérée comme traitement PPAR premier de sa classe thérapeutique pour la cholangite biliaire primitiveEU:IPNIpsen SA
      06/10/20244:54PMGlobeNewswire Inc.Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitisTG:I7GIpsen SA
      06/10/20244:54PMGlobeNewswire Inc.Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitisEU:IPNIpsen SA
      06/10/20244:54PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:CIFRWCipher Mining Inc
      06/10/20244:54PMBusiness WireDutch Bros Inc. Announces Launch of Secondary Public Offering of Class A Common StockNYSE:BROSDutch Bros Inc
      06/10/20244:53PMEdgar (US Regulatory)Form 424B2 - Prospectus [Rule 424(b)(2)]AMEX:VXZiPath Series B S&P 500 VIX MidTerm Futures ETN
      06/10/20244:53PMEdgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:WAYWaystar Holding Corp